305 completed. 305 Phase 2, 34 Phase 1, 34 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 305 | Completed 305 |
| Phase 1 | 34 | Completed 34 |
| Phase 3 | 34 | Completed 34 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone Risperidone 4mg/day, Ashwagandha, Placebo - Schizophrenia Patients, Neuroinflammation | Phase 2 | Completed | Hasanuddin University | 80 | 2025-10-01 | 2026-05-12 |
| A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia KYN-5356 low dose, Placebo, KYN-5356 Medium Dose - Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Completed | Kynexis B.V. | 149 | 2025-08-27 | 2026-10-23 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Placebo, ML-007C-MA BID, ML-007C-MA QD - Schizophrenia | Phase 2 | Completed | MapLight Therapeutics | 307 | 2025-06-27 | 2026-07-09 |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia Structured Supportive Psychotherapy, Risperidone 2 mg - Schizophrenia, Cognitive Dysfunction | Phase 2 | Completed | Hasanuddin University | 46 | 2024-12-01 | 2026-03-17 |
| A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose - SCHIZOPHRENIA 1 (Disorder) | Phase 2 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 363 | 2024-05-23 | 2026-04-24 |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia LB-102 - Schizophrenia | Phase 2 | Completed | LB Pharmaceuticals Inc. | 359 | 2023-11-29 | 2025-10-22 |
| Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia PLIFUS, Sham PLIFUS, MRI - Schizophrenia, Schizophrenia Schizoaffective | Phase 2 | Completed | NYU Langone Health | 15 | 2023-04-06 | 2025-05-30 |
| A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) RL-007 (Inidascamine), Placebo - Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment | Phase 2 | Completed | Recognify Life Sciences | 242 | 2022-12-08 | 2025-07-30 |
| The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training. The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia - Schizophrenia | Phase 2 | Completed | Rakitzi, Stavroula | 35 | 2022-11-01 | 2025-03-05 |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 2 | Completed | Neurocrine Biosciences | 210 | 2022-10-04 | 2025-07-11 |
| Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes Apo-Methylphenidate ER - Schizophrenia Schizoaffective | Phase 2 | Completed | The Royal Ottawa Mental Health Centre | 35 | 2022-09-09 | 2026-08-12 |
| A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Emraclidine 15 mg, Emraclidine 30 mg, Placebo - Schizophrenia | Phase 2 | Completed | AbbVie | 391 | 2022-07-05 | 2025-10-28 |
| A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Placebo, Emraclidine 10 mg, Emraclidine 30 mg - Schizophrenia | Phase 2 | Completed | AbbVie | 385 | 2022-06-30 | 2025-09-17 |
| A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia. WAS123, Aripiprazole (Fixed dose) - Schizophenia Disorder | Phase 2 | Completed | EMS | 121 | 2022-05-10 | 2026-09-25 |
| A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia. JX11502MA, Placebo - Schizophrenia | Phase 1 / Phase 2 | Completed | Zhejiang Jingxin Pharmaceutical Co., Ltd. | 60 | 2022-03-02 | 2024-04-10 |
| Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes Semaglutide, 1.34 mg/mL, Placebo - Schizophrenia, Prediabetic State | Phase 2 | Completed | Jan Frystyk | 154 | 2022-01-01 | 2024-07-08 |
| Schizophrenia Treatment With Photoneuromodulation Photoneuromodulation - Schizophrenia | Phase 2 | Completed | University of Sao Paulo | 30 | 2021-08-01 | 2025-09-29 |
| Memantine Augmentation of Targeted Cognitive Training in Schizophrenia Memantine, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 / Phase 3 | Completed | University of California, San Diego | 62 | 2021-07-06 | 2026-05-18 |
| Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia CPL500036 - low dose, CPL500036 - high dose, Placebo - Schizophrenia | Phase 2 | Completed | Celon Pharma SA | 189 | 2021-05-19 | 2025-09-10 |
Showing 20 of 305. Sign in to see all of them.
Psychotic Disorders (90) · Mental Disorders (25) · Bipolar Disorder (14) · Hallucinations (11) · Cognitive Dysfunction (9) · Schizophrenia Spectrum and Other Psychotic Disorders (8) · Tobacco Use Disorder (6) · Depression (5) · Smoking Cessation (5) · Cigarette Smoking (4) · Cognition Disorders (4) · Delusions (4) · Depressive Disorder, Major (4) · Inflammation (4)
Schizophrenia Spectrum and Other Psychotic Disorders (297) · Mental Disorders (280) · Pathological Conditions, Signs and Symptoms (29) · Behavior (28) · Nervous System Diseases (23) · Signs and Symptoms (22) · Neurologic Manifestations (17) · Neurobehavioral Manifestations (15) · Bipolar and Related Disorders (14) · Neurocognitive Disorders (14) · Behavioral Symptoms (13) · Mood Disorders (13) · Chemically-Induced Disorders (12) · Perceptual Disorders (11) · Substance-Related Disorders (10)
Risperidone (28) · Olanzapine (18) · Aripiprazole (14) · Lurasidone Hydrochloride (6) · Paliperidone Palmitate (6) · ziprasidone (6) · Cannabidiol (5) · LY 2140023 (5) · Oxytocin (5) · Therapeutics (5) · Cognitive Behavioral Therapy (4) · Galantamine (4) · Glycine (4) · Quetiapine Fumarate (4) · Sarcosine (4)
Yale University (11) · Otsuka Pharmaceutical Development & Commercialization, Inc. (9) · University of Maryland, Baltimore (8) · Merck Sharp & Dohme LLC (7) · China Medical University Hospital (6) · Nathan Kline Institute for Psychiatric Research (6) · Tanabe Pharma Corporation (6) · University of California, San Diego (6) · Denovo Biopharma LLC (5) · GlaxoSmithKline (5) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (5) · Novartis Pharmaceuticals (5) · AstraZeneca (4) · Forest Laboratories (4) · H. Lundbeck A/S (4)
United States (186) · Russia (23) · Taiwan (19) · Germany (18) · Japan (18) · Ukraine (17) · Canada (15) · Romania (13) · Bulgaria (12) · Poland (12) · France (10) · India (10) · Brazil (9) · Hungary (8) · South Korea (8)
Scott W Woods, MD (4) · Daniel C Javitt, MD, PhD (3) · Robert W Buchanan, M.D. (3) · Alan Breier, MD (2)
PMID 28433500, PMID 25890643, PMID 33854317, PMID 34091867, PMID 22992330, PMID 26879587, PMID 27188270, PMID 28318835, PMID 28692485, PMID 32141724, PMID 36369028, PMID 37142273, PMID 37230961, PMID 38085556, PMID 10473315, PMID 11483142, PMID 12823166, PMID 15870612, PMID 15936729, PMID 16095473, PMID 16131943, PMID 16571581, PMID 16680620, PMID 16737798, PMID 17284138, PMID 17487227, PMID 17659263, PMID 17690599, PMID 17898352, PMID 18096137, PMID 18381905, PMID 18584319, PMID 18678800, PMID 18923067, PMID 19497249, PMID 19818257, PMID 19887019, PMID 19941696, PMID 20435443, PMID 20728875, PMID 20810586, PMID 20816042, PMID 21145041, PMID 21294997, PMID 21346616, PMID 21969420, PMID 22160487, PMID 22178084, PMID 22388170, PMID 22446565
2016 (4), P50MH082999 (4), 2017 (3), 2008 (2), 2018 (1), I01CX001414 (1), P50MH086383 (1), P50MH103222 (1), R01DA024674 (1), R01MH059807 (1), R01MH060390 (1), R01MH061412 (1), R01MH062554 (1), R01MH063484 (1), R01MH068725 (1)